Literature DB >> 18289135

Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients.

Radovan Malý1, Jirí Masopust, Ladislav Hosák, Katerina Konupcíková.   

Abstract

AIMS: The aim of the present study was to compile a specific algorithm of prevention of venous thromboembolism in hospitalized psychiatric patients because this specific issue has not been addressed sufficiently in the literature.
METHODS: The computer database MEDLINE was searched using key words (schizophrenia OR depression OR bipolar) AND (antipsychotic OR antidepressant) AND (venous thromboembolism OR pulmonary embolism) AND (prevention OR prophylaxis) in 2006.
RESULTS: Based on the literature regarding non-surgical and surgical patients with respect to specificities in mental disorders (obesity induced with psychotropic drugs, possible catatonia, physical restraint, potential dehydration, antipsychotic treatment), a scoring system and a synoptic algorithm of prevention of venous thromboembolism modified for hospitalized psychiatric patients, were suggested.
CONCLUSIONS: According to the authors' knowledge this is the first attempt to establish such guidelines exclusively in psychiatry. Individual preventative clinical measures are suggested, ranging from regular physical exercise of lower extremities to repeated parenteral application of high doses of heparin tailored to every patient's risk for venous thromboembolism. Economic data support implementation of a proposed decision procedure into psychiatric clinical practice. Prospective discussion of its international applicability would be beneficial from both the clinical and the scientific points of view.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18289135     DOI: 10.1111/j.1440-1819.2007.01773.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  16 in total

Review 1.  Anticoagulation and psychotropic medications.

Authors:  Maurice Bachawati
Journal:  Curr Psychiatry Rep       Date:  2010-06       Impact factor: 5.285

Review 2.  Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management.

Authors:  Anna K Jönsson; Olav Spigset; Staffan Hägg
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

3.  Differential expression of 5-HT-related genes in symptomatic pulmonary embolism patients.

Authors:  Yun Jin; Lemin Wang; Qianglin Duan; Zhu Gong; Fan Yang; Yanli Song
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  Idiopathic pulmonary thromboembolism in the course of intensive psychiatric inpatient care: case report and treatment guidelines.

Authors:  Shane J McInerney; Colm McDonald
Journal:  BMJ Case Rep       Date:  2012-09-07

Review 5.  Drug-induced thrombosis: an update.

Authors:  Yuval Ramot; Abraham Nyska; Galia Spectre
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

6.  Extensive Deep Venous Thrombosis in a Patient with Neurolept Malignant Syndrome despite Being on Prophylaxis.

Authors:  Jerrin C Mathew; Unnikrishnan Pillai; Alexander Lacasse
Journal:  Case Rep Psychiatry       Date:  2011-10-19

7.  Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study.

Authors:  Jiří Masopust; Radovan Malý; Ctirad Andrýs; Martin Vališ; Jan Bažant; Ladislav Hosák
Journal:  BMC Psychiatry       Date:  2011-01-03       Impact factor: 3.630

8.  Venous thromboembolism prophylaxis in mental healthcare: do the benefits outweigh the risks?

Authors:  Rashmi Patel
Journal:  BJPsych Bull       Date:  2015-04

9.  Venous thromboembolism following initiation of atypical antipsychotics in two geriatric patients.

Authors:  Thomas J Maestri; Jessica Koenig; Christine Masuda; Tawny L Smith; Erica C Garcia-Pittman
Journal:  Ment Health Clin       Date:  2018-03-23

10.  Deep venous thrombosis and atypical antipsychotics: three cases report.

Authors:  Fatemeh Sheikhmoonesi; Seyyedeh Fatemeh Bahari Saravi
Journal:  Daru       Date:  2012-10-31       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.